These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16570102)

  • 1. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endocannabinoid system and energy metabolism: physiology and pathophysiology].
    Pagotto U; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):74S-82S. PubMed ID: 18773754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?
    Kunos G
    Am J Med; 2007 Sep; 120(9 Suppl 1):S18-24; discussion S24. PubMed ID: 17720356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
    Patti ME
    J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoid system and cardio-metabolic risk.
    Loh KY; Kew ST
    Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
    Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
    Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
    [No Abstract]   [Full Text] [Related]  

  • 14. Minireview: Endocannabinoids and their receptors as targets for obesity therapy.
    de Kloet AD; Woods SC
    Endocrinology; 2009 Jun; 150(6):2531-6. PubMed ID: 19372200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the endocannabinoid system in the control of energy homeostasis.
    Osei-Hyiaman D; Harvey-White J; Bátkai S; Kunos G
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S33-8. PubMed ID: 16570103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.